Loading stock data…
$1.78+0.04 (+2.41%)
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China.
Virax Biolabs Group Limited in the Healthcare sector is trading at $1.78 with a market capitalization of $2M. The stock is currently near its 52-week low of $1.69, remaining 59.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) · Annual | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Total Revenue | $8,561↓ | $156,419↑ | $6,331↓ | $12,423 |
| Gross Profit | -$1,365↓ | $50,590↑ | -$53,067↓ | $7,690 |
| Operating Income | -$5.73M↑ | -$6.14M↓ | -$6.08M↑ | -$6.40M |
| Net Income | -$5.46M↑ | -$6.73M↓ | -$6.06M↓ | -$5.02M |
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United Stat...